Nature Cancer

Article	Citations
Untangling the threads of immunotherapy research	649
Enhancing childhood cancer targetability	459
Shooting for multiplexed pathology with Orion	450
Author Correction: Identification of a clinically efficacious CAR T cell subset in diffuse large B cell lymphoma by dynamic multidimensional single-cell profiling	444
Author Correction: Breaking the performance ceiling for neoantigen immunogenicity prediction	367
A low-coverage liquid biopsy for lung cancer	361
Author Correction: RIOK1 phase separation restricts PTEN translation via stress granules activating tumor growth in hepatocellular carcinoma	334
A single-cell map of dynamic chromatin landscapes of immune cells in renal cell carcinoma	296
Breaking frontiers with multidisciplinary cancer research	276
Author Correction: IL-17A-secreting γδ T cells promote resistance to CDK4/CDK6 inhibitors in HR+HER2− breast cancer via CX3CR1+ macrophages	273
A macrophage-activated abscopal effect	267
An oncolytic circular RNA therapy	245
Considering molecular alterations as pan-cancer tissue-agnostic targets	225
Gut decisions in CAR T cell therapy	221
PARP11 interfer(on)es with CAR T cell efficacy	205
Evolutionary trajectories of IDH-mutant astrocytoma identify molecular grading markers related to cell cycling	161
Different niches for stem cells carrying the same oncogenic driver affect pathogenesis and therapy response in myeloproliferative neoplasms	160
MALAT1 protects dormant tumor cells from immune elimination	157
ZFP281 drives a mesenchymal-like dormancy program in early disseminated breast cancer cells that prevents metastatic outgrowth in the lung	152
Single-cell transcriptomic landscape deciphers olfactory neuroblastoma subtypes and intra-tumoral heterogeneity	149
The proteasome regulator PSME4 modulates proteasome activity and antigen diversity to abrogate antitumor immunity in NSCLC	140
Breast cancer cells survive chemotherapy by activating targetable immune-modulatory programs characterized by PD-L1 or CD80	137
The cGAS–STING pathway and cancer	127
Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer	125
Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial	125

Beating cancer one carbon at a time	123
DePICting T cell–APC crosstalk in cancer	123
Expanding the options for KRAS inhibition	121
Reply to: Ricolinostat is not a highly selective HDAC6 inhibitor	118
Palmitate oxidation drives a pro-metastatic post-translational modification	118
Stress granules shape metabolic reprogramming and drug resistance	116
crossNN is an explainable framework for cross-platform DNA methylation-based classification of tumors	112
Adoptively transferred tumor-specific IL-9-producing cytotoxic CD8+ T cells activate host CD4+ T cells to control tumors with antigen loss	112
A targetable type III immune response with increase of IL-17A expressing CD4+ T cells is associated with immunotherapy-induced toxicity in melanoma	110
The importance of being generous	102
Bone marrow progenitor-like cells against leukemia cure	99
IKAROS and MENIN coordinate therapeutically actionable leukemogenic gene expression in MLL-r acute myeloid leukemia	98
Shaping the microenvironment in peritoneal metastases	98
Targeting PRMT9-mediated arginine methylation suppresses cancer stem cell maintenance and elicits cGAS-mediated anticancer immunity	97
Impact of context-dependent autophagy states on tumor progression	95
Advancing therapeutics in small-cell lung cancer	95
Determinants of resistance and response to melanoma therapy	95
Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma	94
Sarcoma ecotypes determine immunotherapy benefit	93
Innate immunity drives epithelial cell plasticity during prostate tumor formation	93
ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer	92
Antibody avidity meets multiple myeloma	92
Inflammation meets translation in AML	91
Evolving landscape of nasopharyngeal carcinoma therapy	91
Thriving in diverse ecosystems	91
Sex-specific gut microbiota and neutrophil senescence in bladder cancer	90
Cancer-derived mitochondria fuel fibroblasts to become pro-tumorigenic	90
Loss of the receptors ER, PR and HER2 promotes USP15-dependent stabilization of PARP1 in triple-negative breast cancer	89
A multiomic atlas identifies a treatment-resistant, bone marrow progenitor-like cell population in T cell acute lymphoblastic leukemia	88
Proteogenomic landscape of human pancreatic ductal adenocarcinoma in an Asian population reveals tumor cell-enriched and immune-rich subtypes	83
Key insights from ESMO Congress 2025	83
Cycling back to folate metabolism in cancer	78
Circadian regulation of cancer stem cells and the tumor microenvironment during metastasis	78
Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors, which preserve wild-type EGFR signaling	77
INPP5A phosphatase is a synthetic lethal target in GNAQ and GNA11-mutant melanomas	76
A comeback for checkpoint inhibition in multiple myeloma	76
SCRN1 confers hepatocellular carcinoma resistance to ferroptosis by stabilizing GPX4 via STK38-mediated phosphorylation	76
Integrative single-cell analysis of human colorectal cancer reveals patient stratification with distinct immune evasion mechanisms	75
Direct and selective pharmacological disruption of the YAP–TEAD interface by IAG933 inhibits Hippo-dependent and RAS–MAPK-altered cancers	74
Clinical implementation of artificial-intelligence-assisted detection of breast cancer metastases in sentinel lymph nodes: the CONFIDENT-B single-center, non-randomized clinical trial	73
Regulatory T cells play a crucial part in radio-immunotherapy resistance of brain tumors	73
MCL1 inhibitor BRD-810 kills cancer cells while minimizing risk of cardiotoxicity	73
Radiation sparks a dark side in neutrophils	72
Immunosuppressive dura-derived macrophages in leptomeningeal metastasis	72
CHD1 status drives divergent metabolic pathways in SPOP-mutant prostate cancer	72
Radioligand cancer therapy comes to the fore	72
Multimodal data integration improves immunotherapy response prediction	71
Dual inhibition of EGFR and PI3K with a single drug	71
Bispecific antibodies seek out colon cancer stem cells	70
Author Correction: Ectopic JAK–STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistance	70

First-in-class ultralong-target-residence-time p38α inhibitors as a mitosis-targeted therapy for colorectal cancer	69
Multiregion sampling of de novo metastatic prostate cancer reveals complex polyclonality and augments clinical genotyping	68
How AI agents will change cancer research and oncology	67
A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes	66
Concurrent inhibition of tumor growth and metastasis by a lipidated nanophotosensitizer tracing and disabling tumor extracellular vesicles	66
Building a translational cancer dependency map for The Cancer Genome Atlas	66
Efficacy of pembrolizumab and vorinostat combination in patients with recurrent and/or metastatic squamous cell carcinomas: a phase 2 basket trial	65
Immunotargeting of a recurrent AML-specific neoantigen	65
Differential chromatin accessibility and transcriptional dynamics define breast cancer subtypes and their lineages	64
Highlights from the 2025 ASCO Annual Meeting	63
PD-1 instructs a tumor-suppressive metabolic program that restricts glycolysis and restrains AP-1 activity in T cell lymphoma	63
AKTing on XPO1 inhibition in AML	63
Selective targeting of malignant T cells	63
Macrophage mitochondrial fission improves cancer cell phagocytosis induced by therapeutic antibodies and is impaired by glutamine competition	62
Single-cell analysis and functional characterization uncover the stem cell hierarchies and developmental origins of rhabdomyosarcoma	62
Threonine fuels glioblastoma through YRDC-mediated codon-biased translational reprogramming	61
BRD-810 is a highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor models	61
Bispecific chimeric T cell receptors tackle tumor heterogeneity	60
Protein-level mutant p53 reporters identify druggable rare precancerous clones in noncancerous tissues	59
Identification of a clinically efficacious CAR T cell subset in diffuse large B cell lymphoma by dynamic multidimensional single-cell profiling	59
The pro-oncogenic noncanonical activity of a RAS•GTP:RanGAP1 complex facilitates nuclear protein export	59
LCOR mediates interferon-independent tumor immunogenicity and responsiveness to immune-checkpoint blockade in triple-negative breast cancer	59
Advances in antibody-based therapy in oncology	59
The dopamine transporter antagonist vanoxerine inhibits G9a and suppresses cancer stem cell functions in colon tumors	59
Single-cell meta-analyses reveal responses of tumor-reactive CXCL13+ T cells to immune-checkpoint blockade	58
Anything to declare?	58
The tumor microenvironment’s role in the response to immune checkpoint blockade	58
Single-cell analyses implicate ascites in remodeling the ecosystems of primary and metastatic tumors in ovarian cancer	58
Epigenetic plasticity in PDAC	57
Neoadjuvant immunotherapy marks a new era in oncology	57
An antisense RNA promotes breast cancer metastasis via upregulation of NQO1	57
Metabolic symbiosis in pancreatic cancer	56
Myeloma evades T cell-engaging therapies	56
Author Correction: Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signaling	56
Author Correction: Acquired resistance to a GPRC5D-directed T-cell engager in multiple myeloma is mediated by genetic or epigenetic target inactivation	55
An unexpected career in cancer metabolism	55
Estrogen receptor-positive breast cancer subtypes show differential macrophage functions	55
Author Correction: Autotaxin–lysolipid signaling suppresses a CCL11–eosinophil axis to promote pancreatic cancer progression	54
An anti-PD-1–GITR-L bispecific agonist induces GITR clustering-mediated T cell activation for cancer immunotherapy	54
Dual modulation of cytotoxic and checkpoint receptors tunes the efficacy of adoptive Delta One T cell therapy against colorectal cancer	54
There are gremlins in prostate cancer	52
Innate immunity and the NF-κB pathway control prostate stem cell plasticity, reprogramming and tumor initiation	52
SETD2 loss perturbs the kidney cancer epigenetic landscape to promote metastasis and engenders actionable dependencies on histone chaperone complexes	52
P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia	51
Author Correction: An inflammatory state remodels the immune microenvironment and improves risk stratification in acute myeloid leukemia	51
Clonal origin of KMT2A wild-type lineage-switch leukemia following CAR-T cell and blinatumomab therapy	51
In vivo macrophage engineering for renal cancer therapy	51
p53 at the crossroads of tumor immunity	50
Ricolinostat is not a highly selective HDAC6 inhibitor	50
Targeting ADAR1 with a small molecule for the treatment of prostate cancer	50
Clinical and translational attributes of immune-related adverse events	50
Sarcoma microenvironment cell states and ecosystems are associated with prognosis and predict response to immunotherapy	49
PD-L2 expression in senescent cancer cells limits tumor clearance after chemotherapy	49
Tumor evolution metrics predict recurrence beyond 10 years in locally advanced prostate cancer	49
Circumventing the roadblocks to targeting EGFR-driven cancers	49
A single-cell atlas of glioblastoma evolution under therapy reveals cell-intrinsic and cell-extrinsic therapeutic targets	49
Masking T cell engagers mitigates on-target off-tumor activity	47
Breaking the performance ceiling for neoantigen immunogenicity prediction	47
Mitochondrial DNA mutation enhances sensitivity to immunotherapy in melanoma	47
CD103+ regulatory T cells underlie resistance to radio-immunotherapy and impair CD8+ T cell activation in glioblastoma	47
A new sophistication for breast cancer PDXs	46
Unique structural configuration of EV-DNA primes Kupffer cell-mediated antitumor immunity to prevent metastatic progression	46
Understanding the biology of lung cancer brain metastases	46
Tumor-intrinsic sensitivity to the pro-apoptotic effects of IFN-γ is a major determinant of CD4+ CAR T-cell antitumor activity	46
UnitedMet harnesses RNA–metabolite covariation to impute metabolite levels in clinical samples	45
Author Correction: Loss of MAT2A compromises methionine metabolism and represents a vulnerability in H3K27M mutant glioma by modulating the epigenome	43
Overcoming extracellular vesicle-mediated fratricide improves CAR T cell treatment against solid tumors	42
CAR T cell therapy: looking back and looking forward	42
Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: a phase 1b/2 clinical trial and correlative analyses	41
CD8+ T cell killing of MHC class I–deficient tumors	41
Targeting PARP11 to avert immunosuppression and improve CAR T therapy in solid tumors	41
Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis	41
TIGIT and PD-L1 co-blockade promotes clonal expansion of multipotent, non-exhausted antitumor T cells by facilitating co-stimulation	41
The meaning of impact	40
A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/truncal undifferentiated pleomorphic sarcoma	40
Communicating with respect	40
FLASH radiation reprograms lipid metabolism and macrophage immunity and sensitizes medulloblastoma to CAR-T cell therapy	40
Tumor-associated macrophages restrict CD8+ T cell function through collagen deposition and metabolic reprogramming of the breast cancer microenvironment	40
A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAFV600E colorectal tumors	40
Global loss of promoter–enhancer connectivity and rebalancing of gene expression during early colorectal cancer carcinogenesis	39

Artificial intelligence for prostate cancer diagnostics	39
SWIFT-seq enables comprehensive single-cell transcriptomic profiling of circulating tumor cells in multiple myeloma and its precursors	37
CD4+ CAR T cells — more than helpers	37
Leveraging translational insights toward precision medicine approaches for brain metastases	37
Near-infrared optogenetic engineering of bacteria for cancer therapy	37
Leveraging the potential for deintensification in cancer care	37
Spatially resolved transcriptomics and graph-based deep learning improve accuracy of routine CNS tumor diagnostics	36
Efficacy and tolerability of neoadjuvant therapy with Talimogene laherparepvec in cutaneous basal cell carcinoma: a phase II trial (NeoBCC trial)	36
Insight from the ESMO Targeted Anticancer Therapies Congress 2025	36
Therapeutic targeting of the mevalonate–geranylgeranyl diphosphate pathway with statins overcomes chemotherapy resistance in small cell lung cancer	36
Radiopharma pipeline builds ahead of key data	35
EZH2 inhibition remodels the inflammatory senescence-associated secretory phenotype to potentiate pancreatic cancer immune surveillance	35
Commensal metabolite boosts chemotherapy	35
Acute lymphoblastic leukemia displays a distinct highly methylated genome	35
Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens	35
Disparities, aging and childhood cancer	34
The aging lung reawakens dormant tumor cells	34
‘IL-2Rα-biased’ IL-2 for cancer immunotherapy	34
Fibrotic tumors tune metabolism for immune evasion	33
Author Correction: Safety and feasibility of 4-1BB co-stimulated CD19-specific CAR-NK cell therapy in refractory/relapsed large B cell lymphoma: a phase 1 trial	33
Author Correction: Cytokine release syndrome-like serum responses after COVID-19 vaccination are frequent and clinically inapparent under cancer immunotherapy	33
The rapidly evolving paradigm of neoadjuvant immunotherapy across cancer types	32
Cytidine deaminases APOBEC3C and APOBEC3D promote DNA replication stress resistance in pancreatic cancer cells	32
Context-dependent tumor-suppressive BMP signaling in diffuse intrinsic pontine glioma regulates stemness through epigenetic regulation of CXXC5	32
Targeting HIF-1 to treat AML	32
Antibiotic-related dysbiosis in cancer immunotherapy: from preclinical insights to practice-changing evidence	32
Integrative analysis of risk factors for immune-related adverse events of checkpoint blockade therapy in cancer	31
The growing threat of cyberwarfare in cancer healthcare	31
Targeting the histone reader ZMYND8 inhibits antiandrogen-induced neuroendocrine tumor transdifferentiation of prostate cancer	31
ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells	31
The landscape of T cell antigens for cancer immunotherapy	31
Not a generative AI–generated Editorial	30
Publisher Correction: Cancer’s new normal	30
Remodeling cyclophilin A to target KRAS	30
CAR T cell therapy for multiple myeloma	30
Checkpoint blockade regulates T cell fate by supporting co-stimulation	30